BioRestorative Therapies, Inc.
BRTXHealthcare|Biotechnology|US
$1.52
+0.01 (+0.66%)
Tangible Book / Share
$2.84
Cash / Share
$4.05
Financials
Financial Snapshot
Market Cap
$2.1M
Enterprise Value
-$978.8K
Revenue (TTM)
$357.9K
Net Income (TTM)
-$11.1M
Cash & Investments
$3.6M
Net Cash
$3.6M
Free Cash Flow (TTM)
-$11.9M
Operating CF (TTM)
-$11.8M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$3.6M
Quarterly Burn
$3.0M
Monthly Burn
$984.8K
Est. Runway
~1.2 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $31.8K | $451.7K | $117.5K | $1.7K | $3.1M | $21.0M | $14.7M | $11.1M | $10.7M | $3.0M | $3.6M | |
| Operating Cash Flow | -$5.0M | -$3.9M | -$5.1M | -$6.9M | -$2.0M | -$3.3M | -$5.9M | -$6.4M | -$8.2M | -$10.8M | -$11.8M | |
| Free Cash Flow | -$5.2M | -$3.9M | -$5.1M | -$7.0M | -$2.0M | -$3.4M | -$6.4M | -$6.6M | -$8.3M | -$10.9M | -$11.9M | |
| Capital Expenditure | -$188.8K | -$3.6K | -$12.9K | -$35.6K | $0.00 | -$30.7K | -$440.2K | -$171.0K | -$106.2K | -$116.1K | -$79.7K | |
| Financing Cash Flow | $5.1M | $4.3M | $4.8M | $6.8M | $5.0M | $21.3M | $0.00 | $2.3M | $7.4M | $2.9M | $6.2M |
R&D Spending
R&D (TTM)
$9.4M
R&D Intensity
2619.4%
R&D Growth vs Prior
-7.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.4K | $81.0K | $111.0K | $130.0K | $77.0K | $46.0K | $119.8K | $145.8K | $401.0K | $359.7K | $357.9K | |
| R&D Expense | $2.9M | $2.2M | $1.5M | $1.7M | $876.8K | $729.1K | $3.5M | $4.0M | $5.3M | $10.1M | $9.4M | |
| R&D % of Revenue | 7931.7% | 2657.3% | 1363.2% | 1324.9% | 1138.7% | 1584.9% | 2932.7% | 2767.2% | 1333.8% | 2806.4% | 2619.4% | |
| SG&A | $4.9M | $6.3M | $6.2M | $6.8M | $2.0M | $25.6M | $15.6M | $11.3M | $6.6M | $5.9M | $5.2M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.4K | $81.0K | $111.0K | $130.0K | $77.0K | $46.0K | $119.8K | $145.8K | $401.0K | $359.7K | $357.9K | |
| Cost of Revenue | $102.00 | $259.3K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $28.1K | $23.8K | $28.3K | |
| Gross Profit | $36.3K | -$178.3K | $111.0K | $130.0K | $77.0K | $46.0K | $119.8K | $145.8K | $372.9K | $335.9K | $329.6K | |
| R&D | $2.9M | $2.2M | $1.5M | $1.7M | $876.8K | $729.1K | $3.5M | $4.0M | $5.3M | $10.1M | $9.4M | |
| SG&A | $4.9M | $6.3M | $6.2M | $6.8M | $2.0M | $25.6M | $15.6M | $11.3M | $6.6M | $5.9M | $5.2M | |
| Operating Income | -$7.8M | -$8.4M | -$7.6M | -$8.4M | -$2.8M | -$26.3M | -$18.9M | -$15.2M | -$11.6M | -$15.6M | -$14.2M | |
| Interest Expense | $763.9K | $1.1M | $3.2M | $5.1M | $1.6M | $1.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$8.6M | -$9.4M | -$12.5M | -$14.6M | -$11.3M | -$44.3M | -$13.2M | -$10.4M | -$9.0M | -$14.2M | -$11.1M | |
| Net Income | -$8.6M | -$9.4M | -$12.5M | -$14.6M | -$11.3M | -$44.3M | -$13.2M | -$10.4M | -$9.0M | -$14.2M | -$11.1M | |
| EPS (Diluted) | -168000.00 | -139200.00 | -131246.40 | -52601.60 | -571.20 | -746.00 | -73.00 | -49.40 | -23.20 | -31.60 | -22.20 | |
| EBITDA | -$7.6M | -$8.1M | -$9.1M | -$9.3M | -$9.5M | -$42.4M | -$13.1M | -$15.0M | -$8.8M | -$14.0M | -$10.8M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.18 | 0.21 | 0.39 | 0.45 | 0.89 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.8K | $451.7K | $117.5K | $1.7K | $3.1M | $21.0M | $1.7M | $884.4K | $547.9K | $1.5M | $3.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $13.0M | $10.2M | $10.2M | $1.4M | $479.4K | |
| Total Current Assets | $61.7K | $519.7K | $181.0K | $68.9K | $3.2M | $21.5M | $15.1M | $11.4M | $11.1M | $3.1M | $3.8M | |
| Total Assets | $1.6M | $1.8M | $1.2M | $1.5M | $4.3M | $22.5M | $16.4M | $12.6M | $12.3M | $4.1M | $4.6M | |
| Total Current Liabilities | $5.8M | $8.4M | $9.3M | $13.7M | $1.0M | $363.8K | $6.0M | $2.6M | $3.7M | $3.7M | $1.6M | |
| Long-Term Debt | $297.8K | $194.3K | $523.9K | $0.00 | $4.3M | $191.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.6M | $8.6M | $9.8M | $14.2M | $5.7M | $856.5K | $6.1M | $2.6M | $3.7M | $3.7M | $1.6M | |
| Stockholders' Equity | -$5.0M | -$6.8M | -$8.6M | -$12.8M | -$1.3M | $21.6M | $10.3M | $10.0M | $8.5M | $356.7K | $3.0M | |
| Retained Earnings | -$42.0M | -$51.4M | -$63.9M | -$78.6M | -$89.8M | -$134.1M | -$136.3M | -$146.7M | -$155.7M | -$169.9M | -$172.1M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0M | -$3.9M | -$5.1M | -$6.9M | -$2.0M | -$3.3M | -$5.9M | -$6.4M | -$8.2M | -$10.8M | -$11.8M | |
| Capital Expenditure | -$188.8K | -$3.6K | -$12.9K | -$35.6K | $0.00 | -$30.7K | -$440.2K | -$171.0K | -$106.2K | -$116.1K | -$79.7K | |
| Free Cash Flow | -$5.2M | -$3.9M | -$5.1M | -$7.0M | -$2.0M | -$3.4M | -$6.4M | -$6.6M | -$8.3M | -$10.9M | -$11.9M | |
| Investing Cash Flow | -$188.8K | -$3.6K | -$12.9K | -$35.6K | $0.00 | -$30.7K | -$13.4M | $3.3M | $514.5K | $8.9M | $7.5M | |
| Financing Cash Flow | $5.1M | $4.3M | $4.8M | $6.8M | $5.0M | $21.3M | $0.00 | $2.3M | $7.4M | $2.9M | $6.2M | |
| Issuance of Stock | $3.5M | $1.1M | $175.0K | $1.7M | $10.0K | $21.1M | $0.00 | $2.3M | $0.00 | $3.1M | $6.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.4M | $2.2M | $4.2M | $5.2M | $5.5M | $250.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.5M | $3.6M | $2.4M | $1.7M | $691.7K | $23.1M | $12.6M | $7.8M | $2.8M | $3.3M | $1.6M | |
| Net Change in Cash | -$134.7K | $419.9K | -$334.2K | -$115.9K | $3.1M | $18.0M | -$19.3M | -$829.4K | -$336.5K | $963.3K | $1.9M |
Dilution Tracker
Shares outstanding grew 2178.5% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+2178.5%
Stock Issuance (TTM)
$6.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.18 | 0.21 | 0.39 | 0.45 | 0.89 | |
| Change vs Prior % | — | 33.3% | 39.7% | 192.6% | 6998.9% | 200.9% | 204.6% | 16.6% | 84.1% | 15.8% | 97.1% | |
| Stock Issuance | $3.5M | $1.1M | $175.0K | $1.7M | $10.0K | $21.1M | $0.00 | $2.3M | $0.00 | $3.1M | $6.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.5M | $3.6M | $2.4M | $1.7M | $691.7K | $23.1M | $12.6M | $7.8M | $2.8M | $3.3M | $1.6M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 99.7% | -220.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% | 93.4% | 92.1% | |
| Operating Margin % | -21447.6% | -10338.6% | -6889.8% | -6486.2% | -3574.1% | -57191.0% | -15745.8% | -10439.5% | -2881.6% | -4350.1% | -3975.0% | |
| Net Margin % | -23755.4% | -11660.1% | -11277.3% | -11267.6% | -14639.9% | -96311.5% | -11037.0% | -7145.2% | -2239.2% | -3959.4% | -3089.6% | |
| EBITDA Margin % | -20943.3% | -9997.6% | -8158.2% | -7147.3% | -12352.2% | -92171.3% | -10936.4% | -10268.7% | -2192.1% | -3901.0% | -3030.7% | |
| FCF Margin % | -14279.8% | -4762.3% | -4610.4% | -5349.5% | -2551.0% | -7305.6% | -5303.3% | -4527.6% | -2078.9% | -3031.7% | -3324.6% | |
| ROE % | 172.7% | 138.1% | 144.9% | 114.7% | 846.6% | -205.1% | -128.5% | -104.1% | -105.3% | -3992.2% | -423.8% | |
| ROA % | -546.6% | -537.1% | -1049.8% | -999.0% | -259.3% | -197.3% | -80.5% | -82.6% | -73.1% | -349.1% | -238.3% | |
| ROIC % | 324.1% | 267.8% | 172.4% | 170.8% | -79.5% | -118.1% | -178.1% | -149.7% | -135.4% | -4386.1% | -464.9% | |
| R&D / Revenue % | 7931.7% | 2657.3% | 1363.2% | 1324.9% | 1138.7% | 1584.9% | 2932.7% | 2767.2% | 1333.8% | 2806.4% | 2619.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -94.2% | 122.8% | 37.0% | 17.1% | -40.8% | -40.3% | 160.4% | 21.7% | 175.0% | -10.3% | |
| Gross Profit | -90.1% | -591.7% | 162.3% | 17.1% | -40.8% | -40.3% | 160.4% | 21.7% | 155.8% | -9.9% | |
| Operating Income | -8.7% | -7.4% | 8.7% | -10.3% | 67.4% | -855.9% | 28.3% | 19.3% | 24.1% | -35.4% | |
| Net Income | -9.0% | -9.4% | -32.5% | -17.0% | 23.0% | -293.0% | 70.2% | 21.2% | 13.8% | -58.6% | |
| EPS (Diluted) | 34.4% | 17.1% | 5.7% | 59.9% | 98.9% | -30.6% | 90.2% | 32.3% | 53.0% | -36.2% | |
| Operating Cash Flow | -60.2% | 23.0% | -32.5% | -35.5% | 71.6% | -69.5% | -77.6% | -8.7% | -28.0% | -31.1% | |
| Free Cash Flow | -44.0% | 25.7% | -32.7% | -35.9% | 71.8% | -71.1% | -89.1% | -3.9% | -26.3% | -30.8% | |
| R&D Expense | 37.0% | -25.4% | -29.7% | 13.8% | -49.1% | -16.9% | 381.9% | 14.8% | 32.6% | 88.7% | |
| SG&A Expense | -8.9% | 27.3% | -0.9% | 9.5% | -71.5% | 1212.6% | -39.2% | -27.3% | -41.9% | -10.5% | |
| Total Assets | -21.7% | 11.3% | -32.2% | 23.0% | 196.5% | 416.5% | -26.8% | -23.3% | -2.6% | -66.8% | |
| Book Value / Share | 22.2% | -2.5% | 9.5% | 49.5% | 99.9% | 639.0% | -84.4% | -16.6% | -53.7% | -96.4% | |
| Debt | 64.4% | 69.8% | 13.3% | 88.9% | -38.9% | -86.0% | -55.0% | -46.2% | -100.0% | 0.0% | |
| Diluted Shares | 64.5% | 33.3% | 39.7% | 192.6% | 6998.9% | 200.9% | 204.6% | 16.6% | 84.1% | 15.8% |
Valuation
P/E (TTM)At Loss
P/S5.87
10Y Low / Med / High0.86 / 83.05 / 370.35
P/B0.45
10Y Low / Med / High0.24 / 0.97 / 29.75
EV/EBITDA0.09
EV/Revenue-2.74
10Y Low / Med / High25.30 / 71.26 / 428.79
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$2.84
Net Current Assets / Share
$1.58
Graham Net-Net
$2.24
Cash / Share
$4.05
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1.57 | -2.13 | -0.55 | -0.01 | -0.97 | -0.12 | -0.75 | -0.70 | -1.23 | -0.75 | -0.07 | |
| P/S Ratio | 370.35 | 248.49 | 61.62 | 0.86 | 141.48 | 112.06 | 83.05 | 50.34 | 27.69 | 29.50 | 5.87 | |
| P/B Ratio | -2.69 | -2.94 | -0.79 | -0.01 | -8.18 | 0.24 | 0.97 | 0.73 | 1.30 | 29.75 | 0.45 | |
| EV/EBITDA | -2.05 | -2.88 | -1.20 | -0.86 | -1.33 | 0.36 | -0.65 | -0.44 | -1.20 | -0.65 | 0.09 | |
| EV/Revenue | 428.79 | 288.13 | 97.95 | 61.14 | 163.91 | -330.46 | 71.26 | 45.39 | 26.32 | 25.30 | -2.74 |
Analyst Estimates & Quality
Altman Z-Score
-58.35
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $2.5M | $3.1M | $3.8M |
| Net Income | -$3.0M | -$2.6M | -$3.0M |
| EPS | $-6.60 | $-5.80 | $-6.60 |
| # Analysts (EPS) | 1 | 1 | 1 |
Revenue Segments
By Product
| Segment | 2013 | 2014 | 2015 | 2024 | 2025 |
|---|---|---|---|---|---|
| Stem Pearls Skincare Products | $1.7K | $2.2K | $425.00 | — | — |
| Product | — | — | — | $300.0K | $300.0K |
| Royalty | — | — | — | $101.0K | $59.7K |